More Fortune 500 Power MovesLeeny Oberg, CFO and EVP of development at Marriott International (
No. 171) has decided to retire effective March 31, 2026, after spending more than two decades with the U.S. hotel operator. Oberg, CFO since 2016, will be succeeded by
Jen Mason, who joined Marriott in 1992 and currently serves as global officer, treasurer and risk management. Mason is also a former CFO of the U.S. and Canada at the company.
Shawn Hill was promoted to the role of EVP and chief development officer, effective Jan. 1. Oberg has been in that role since February 2023.
Daniel S. Tucker, EVP and CFO of
Southern Company (
No. 161), an energy provider, plans to retire.
David P. Poroch, currently SVP, comptroller and chief accounting officer, was promoted to succeed Tucker, effective July 31. Tucker will transition to a senior advisory role reporting to the CEO until his retirement on Oct. 1. Poroch began his career with Southern Company in 2012 as VP and chief audit executive of Southern Company Services. From there, he served as EVP, CFO and treasurer of Georgia Power and then EVP and CFO at Southern Company Gas in 2021. Before joining Southern Company, he was a partner with Deloitte & Touche LLP.
Every Friday morning, the weekly Fortune 500 Power Moves column tracks Fortune 500 company C-suite shifts—
see the most recent edition.
More notable moves this week:Mukul Mehta was promoted to CFO of pharmaceutical company
Novartis (ECN), effective March 16, 2026. Mukul succeeds Harry Kirsch, who has served as CFO since 2013, and will retire from Novartis after a 22-year career with the company. Harry will continue in his role as CFO until March 15, 2026. Mukul brings over 20 years of experience at Novartis. He was recently appointed to the role of head of BPA, Digital Finance and Tax, where he will continue until March of next year. His career includes serving as CFO International for three years, ad-interim President International, CFO Pharmaceuticals business unit, CFO Novartis Business Services, CFO Pharmaceuticals Europe business, and Country CFO of France, Poland, and Norway.
Brandy Richardson was appointed CFO of multi-brand luxury retailer
Saks Global, effective Aug. 18. Richardson succeeds Interim CFO Mark Weinsten, who joined Saks Global to lead the company's finance organization through the initial stages of its transformation following its acquisition of Neiman Marcus Group (NMG) in December 2024. With nearly 25 years of experience, Richardson joins Saks Global from Tailored Brands, Inc., where she has served as EVP and CFO. Richardson spent the majority of her career at NMG, where she held several finance leadership roles of increasing responsibility over her 15-year tenure.
Sandy Mahatme was appointed CFO and chief business officer of
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company. Mahatme joins Vor Bio with more than 30 years of executive leadership experience. He most recently served as president, chief operating officer, and CFO of National Resilience, Inc., a biomanufacturing company he cofounded in 2020.
Mark Mesler has stepped down from his position as CFO of Archer Aviation Inc. (NYSE: ACHR), effective July 7, according to an
SEC filing. Mesler had been on medical leave since September 2024. During his absence, Priya Gupta has served as CFO and acting principal financial officer. Gupta will continue in these roles. Harsh Rungta will also remain as SVP of finance and chief accounting officer and principal accounting officer.
Karyn Ovelmen, EVP and CFO of
Newmont (NYSE: NEM), one of the world’s biggest gold miners, has resigned, effective July 11. She will be replaced on an interim basis by Chief Legal Officer Peter Wexler while the company searches for a permanent replacement.
Sarah C. Young was appointed CFO at
Bell Partners, a privately held company specializing in apartment investment and management, and will succeed John Tomlinson upon his planned retirement effective Aug. 22. Young joined the company on July 14 and will report to Lili Dunn, CEO and president of Bell Partners. After his retirement, Tomlinson will remain as an advisor to the company through the end of 2025. Young previously served as CFO and senior managing director at Quarterra Group, a subsidiary of homebuilder Lennar, where she worked for 10 years. Before that, Young was part of the finance group at Walton Street Capital.
Corleen Roche was appointed CFO of
Iovance Biotherapeutics, Inc. (Nasdaq: IOVA), a commercial biotechnology company, effective Aug. 6. Roche brings to the role 30 years of experience in the biotech and life sciences industry. Most recently, she served as CFO of CG Oncology. Her previous roles included CFO of Immunome, U.S. CFO at Biogen, North America CFO of CSL Behring, and various CFO roles within Sandoz, Wyeth and Pfizer.